Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs
<b>Background:</b> Fecal calprotectin has emerged as a significant, validated, and non-invasive biomarker allowing for the evaluation of inflammatory bowel disease. Our study assessed the reliability of the use of faecal calprotectin as a valuable tool in the management of psoriatic pati...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/11/2968 |
| _version_ | 1827644890471727104 |
|---|---|
| author | Eugenia Veronica Di Brizzi Annachiara Rocco Graziella Babino Dario Buononato Giuseppe Argenziano Anna Balato |
| author_facet | Eugenia Veronica Di Brizzi Annachiara Rocco Graziella Babino Dario Buononato Giuseppe Argenziano Anna Balato |
| author_sort | Eugenia Veronica Di Brizzi |
| collection | DOAJ |
| description | <b>Background:</b> Fecal calprotectin has emerged as a significant, validated, and non-invasive biomarker allowing for the evaluation of inflammatory bowel disease. Our study assessed the reliability of the use of faecal calprotectin as a valuable tool in the management of psoriatic patients on biological therapy. <b>Methods:</b> This was a single-centre prospective study including adult patients affected by moderate-to-severe psoriasis starting biological therapy. Faecal calprotectin levels were evaluated at baseline and at week 24 (W24) of treatment in all enrolled patients. <b>Results:</b> Overall, 129 patients were enrolled. The mean baseline faecal calprotectin levels were 74.7 μg/g and a significant reduction was detected at W24 of biological therapy (57.5 μg/g). An analysis of faecal CP values stratified by therapy type was performed. No significant reduction was assessed at W24 for any of the anti-IL17 drugs, whereas a significant reduction was detected for all IL23 inhibitors. <b>Conclusions:</b> Our study showed the potential use of faecal CP levels as a valuable tool for exploring intestinal inflammation in the management of psoriatic patients undergoing treatment with biologic drugs. |
| first_indexed | 2024-03-09T18:27:43Z |
| format | Article |
| id | doaj.art-bf170670bc8547aa81b27fc90b3a9445 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T18:27:43Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-bf170670bc8547aa81b27fc90b3a94452023-11-24T07:47:00ZengMDPI AGBiomedicines2227-90592022-11-011011296810.3390/biomedicines10112968Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic DrugsEugenia Veronica Di Brizzi0Annachiara Rocco1Graziella Babino2Dario Buononato3Giuseppe Argenziano4Anna Balato5Dermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, ItalyDermatology Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy<b>Background:</b> Fecal calprotectin has emerged as a significant, validated, and non-invasive biomarker allowing for the evaluation of inflammatory bowel disease. Our study assessed the reliability of the use of faecal calprotectin as a valuable tool in the management of psoriatic patients on biological therapy. <b>Methods:</b> This was a single-centre prospective study including adult patients affected by moderate-to-severe psoriasis starting biological therapy. Faecal calprotectin levels were evaluated at baseline and at week 24 (W24) of treatment in all enrolled patients. <b>Results:</b> Overall, 129 patients were enrolled. The mean baseline faecal calprotectin levels were 74.7 μg/g and a significant reduction was detected at W24 of biological therapy (57.5 μg/g). An analysis of faecal CP values stratified by therapy type was performed. No significant reduction was assessed at W24 for any of the anti-IL17 drugs, whereas a significant reduction was detected for all IL23 inhibitors. <b>Conclusions:</b> Our study showed the potential use of faecal CP levels as a valuable tool for exploring intestinal inflammation in the management of psoriatic patients undergoing treatment with biologic drugs.https://www.mdpi.com/2227-9059/10/11/2968calprotectinfaecal calprotectinpsoriasisbiological therapyinflammatory bowel disease |
| spellingShingle | Eugenia Veronica Di Brizzi Annachiara Rocco Graziella Babino Dario Buononato Giuseppe Argenziano Anna Balato Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs Biomedicines calprotectin faecal calprotectin psoriasis biological therapy inflammatory bowel disease |
| title | Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs |
| title_full | Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs |
| title_fullStr | Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs |
| title_full_unstemmed | Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs |
| title_short | Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs |
| title_sort | evaluation of the role of faecal calprotectin in the management of psoriatic patients under treatment with biologic drugs |
| topic | calprotectin faecal calprotectin psoriasis biological therapy inflammatory bowel disease |
| url | https://www.mdpi.com/2227-9059/10/11/2968 |
| work_keys_str_mv | AT eugeniaveronicadibrizzi evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs AT annachiararocco evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs AT graziellababino evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs AT dariobuononato evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs AT giuseppeargenziano evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs AT annabalato evaluationoftheroleoffaecalcalprotectininthemanagementofpsoriaticpatientsundertreatmentwithbiologicdrugs |